Jennifer R Blase David Frame Thomas F Michniacki Kelly Walkovich
10.3389/fimmu.2022.863177
Front Immunol
2022 Apr 19;13:863177.
itp (idiopathic thrombocytopenic purpura) case report obinutuzumab rituximab serum sickness
CC BY
https://pubmed.ncbi.nlm.nih.gov/35514985/
Purpura, Thrombocytopenic, Idiopathic / chemically induced Purpura, Thrombocytopenic, Idiopathic / diagnosis Purpura, Thrombocytopenic, Idiopathic / drug therapy Serum Sickness / chemically induced Serum Sickness / diagnosis
Purpura, Thrombocytopenic, Idiopathic / chemically induced Purpura, Thrombocytopenic, Idiopathic / diagnosis Purpura, Thrombocytopenic, Idiopathic / drug therapy Serum Sickness / chemically induced Serum Sickness / diagnosis Case Reports Review Antibodies, Monoclonal, Humanized Antibodies, Monoclonal, Murine-Derived / therapeutic use Antibodies, Neutralizing / therapeutic use Female Humans Rituximab / adverse effects Antibodies, Monoclonal, Humanized Antibodies, Monoclonal, Murine-Derived Antibodies, Neutralizing Rituximab obinutuzumab
PMC9061985
35514985
Case Report: Use of Obinutuzumab as an Alternative Monoclonal Anti-CD20 Antibody in a Patient With Refractory Immune Thrombocytopenia Complicated by Rituximab-Induced Serum Sickness and Anti-Rituximab Antibodies
2022